These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 27387538)
61. Influence of Amlodipine Enantiomers on Human Microsomal Cytochromes P450: Stereoselective Time-Dependent Inhibition of CYP3A Enzyme Activity. Krasulova K; Holas O; Anzenbacher P Molecules; 2017 Nov; 22(11):. PubMed ID: 29099769 [TBL] [Abstract][Full Text] [Related]
62. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes - detailed studies on CYP3A inhibitors. Kahma H; Paludetto MN; Neuvonen M; Kurkela M; Filppula AM; Niemi M; Backman JT Eur J Pharm Sci; 2024 Jul; 198():106735. PubMed ID: 38423227 [TBL] [Abstract][Full Text] [Related]
63. Deoxyshikonin reversibly inhibits cytochrome P450 2B6. Kim JH; Choi SM; Shreatha R; Jeong GS; Jeong TC; Lee S Biopharm Drug Dispos; 2020 Apr; 41(4-5):221-225. PubMed ID: 32364297 [TBL] [Abstract][Full Text] [Related]
64. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. Lu C; Suri A; Shyu WC; Prakash S Biopharm Drug Dispos; 2014 Dec; 35(9):543-52. PubMed ID: 25264242 [TBL] [Abstract][Full Text] [Related]
65. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Marill J; Capron CC; Idres N; Chabot GG Biochem Pharmacol; 2002 Mar; 63(5):933-43. PubMed ID: 11911845 [TBL] [Abstract][Full Text] [Related]
66. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A. Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854 [TBL] [Abstract][Full Text] [Related]
67. Probe substrates assay estimates the effect of polyphyllin H on the activity of cytochrome P450 enzymes in human liver microsomes. Wang E; Wang M; Gao M Pharmacol Res Perspect; 2024 Oct; 12(5):e70002. PubMed ID: 39210686 [TBL] [Abstract][Full Text] [Related]
68. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936 [TBL] [Abstract][Full Text] [Related]
69. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Doehmer J; Weiss G; McGregor GP; Appel K Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605 [TBL] [Abstract][Full Text] [Related]
70. Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms. Shinde DD; Kim MJ; Jeong ES; Kim YW; Lee JW; Shin JG; Kim DH J Toxicol Environ Health A; 2014; 77(22-24):1419-30. PubMed ID: 25343291 [TBL] [Abstract][Full Text] [Related]
71. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids. Salminen KA; Meyer A; Jerabkova L; Korhonen LE; Rahnasto M; Juvonen RO; Imming P; Raunio H Phytomedicine; 2011 Apr; 18(6):533-8. PubMed ID: 20851588 [TBL] [Abstract][Full Text] [Related]
72. Inhibitory Mechanisms of Myricetin on Human and Rat Liver Cytochrome P450 Enzymes. Lou D; Bao SS; Li YH; Lin QM; Yang SF; He JY Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):611-618. PubMed ID: 30825074 [TBL] [Abstract][Full Text] [Related]
73. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Korhonen LE; Turpeinen M; Rahnasto M; Wittekindt C; Poso A; Pelkonen O; Raunio H; Juvonen RO Br J Pharmacol; 2007 Apr; 150(7):932-42. PubMed ID: 17325652 [TBL] [Abstract][Full Text] [Related]
75. Ji X; Ding B; Wu X; Liu F; Yang F Xenobiotica; 2021 Mar; 51(3):262-267. PubMed ID: 33115303 [TBL] [Abstract][Full Text] [Related]
76. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988 [TBL] [Abstract][Full Text] [Related]
77. Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Ji HY; Lee HW; Kim HH; Kim DS; Yoo M; Kim WB; Lee HS Xenobiotica; 2004; 34(11-12):973-82. PubMed ID: 15801542 [TBL] [Abstract][Full Text] [Related]
78. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661 [TBL] [Abstract][Full Text] [Related]
79. In vitro Inhibitory Effects of Isofraxidin on Human Liver Cytochrome P450 Enzymes. Song X; Dong G; Zhou Y Pharmacology; 2019; 103(3-4):120-127. PubMed ID: 30544127 [TBL] [Abstract][Full Text] [Related]
80. [Inhibitory effect of imperatorin and isoimperatorin on activity of cytochrome P450 enzyme in human and rat liver microsomes]. Cao Y; Zhong YH; Yuan M; Li H; Zhao CJ Zhongguo Zhong Yao Za Zhi; 2013 Apr; 38(8):1237-41. PubMed ID: 23944042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]